SANTA MONICA, Calif. - GoodRx Holdings, Inc. (NASDAQ: GDRX), a leading platform for prescription savings, has announced preliminary unaudited financial results for the fourth quarter and the full year ended December 31, 2023, which are expected to surpass the company's previous guidance.
The company anticipates fourth-quarter revenue and Adjusted Revenue to be between $195 million and $197 million, marking a year-over-year increase of approximately 6% to 7%. For the full year, revenue is projected to be in the range of $749 million to $751 million, while Adjusted Revenue is expected to be slightly higher, between $759 million and $761 million. This represents a slight decrease from the previous year, with full-year revenue down about 2% and Adjusted Revenue down about 1%.
Adjusted EBITDA Margin for both the fourth quarter and the full year is predicted to be at the upper end of the guidance range provided on November 9, 2023. The improved performance in the fourth quarter, particularly regarding Adjusted EBITDA Margin, is primarily attributed to organic growth in Prescription Transactions Revenue. This growth has been driven by factors such as increased seasonal respiratory illnesses, mild weather conditions, and favorable aspects of certain client contracts.
GoodRx has noted that these preliminary results have not been audited or reviewed by their independent accounting firm and may be subject to change upon completion of their financial closing procedures. The final financial results for the fourth quarter and full year 2023 are scheduled to be reported on or about February 29, 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.